Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer
Autore:
Sabbatini, P; Larson, SM; Kremer, A; Zhang, ZF; Sun, M; Yeung, H; Imbriaco, M; Horak, I; Conolly, M; Ding, C; Ouyang, P; Kelly, WK; Scher, HI;
Indirizzi:
Memol,oan Kettering Canc Ctr, Genitourinary Oncol Serv, Div Solid Tumor Onc Mem Sloan Kettering Canc Ctr New York NY USA 10021 v, Div Solid Tumor Onc Mem Sloan Kettering Canc Ctr, Dept Med Imaging, Nucl Med Serv, New York, NY Mem Sloan Kettering Canc Ctr New York NY USA 10021 Med Serv, New York, NY MemUSAoan Kettering Canc Ctr, Dept Biostat & Epidemiol, New York, NY 10021Mem Sloan Kettering Canc Ctr New York NY USA 10021 ol, New York, NY 10021 Janssen Res Fdn, Titusville, NJ USA Janssen Res Fdn Titusville NJ USAJanssen Res Fdn, Titusville, NJ USA
Titolo Testata:
JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 3, volume: 17, anno: 1999,
pagine: 948 - 957
SICI:
0732-183X(199903)17:3<948:PSOEOD>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
METASTATIC CARCINOMA; CLINICAL-TRIALS; SCAN; STRATIFICATION; CHEMOTHERAPY; ANTIGEN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
40
Recensione:
Indirizzi per estratti:
Indirizzo: Scher, HI Memol,oan Kettering Canc Ctr, Genitourinary Oncol Serv, Div Solid Tumor Onc Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY USA 10021
Citazione:
P. Sabbatini et al., "Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer", J CL ONCOL, 17(3), 1999, pp. 948-957

Abstract

Purpose: To evaluate the prognostic significance of a bone scan index (BSI) based on the weighted proportion of tumor involvement in individual bones, in relation to other factors and to survival in patients with androgen-independent prostate cancer. Patients and Methods: Baseline radionuclide bone scans were reviewed in 191 assessable patients with androgen-independent disease who were enrolled onto an open, randomized trial of liarozole versus prednisone. The extent ofskeletal involvement was assessed by scoring each scan using the BSI and independently according to the number of metastatic lesions. The relationship of the scored bone involvement to other known prognostic factors was explored in single- and multiple-variable analyses. Results: In single-variable analyses, the pretreatment factors found to beassociated with survival were age (P = .0446), performance status (P =.0005), baseline prostate-specific antigen (P = .0001), hemoglobin (P =.0001), alkaline phosphatase (P = .0002), AST (P = .0021), lactate dehydrogenase (P=.0001), and treatment (P = .0098). The extent of osseous disease was significant using both the BSI (P = .0001) and the number of lesions present (P= .0001). In multiple-variable proportional hazards analyses, only BSI, age, hemoglobin, lactate dehydrogenase, and treatment arm were associated with survival. When the patient population was divided into three equal groups, with BSI values of < 1.4%, 1.4% to 5.1%, and > 5.1%, median survivals of 18.3, 15.5, and 8.1 months, respectively, were observed (P = .0079). Conclusion: The BSI quantifies the extent of skeletal involvement by tumor. It allows the identification of patients with distinct prognoses for stratificatian in clinical trials. Further study is needed to assess the utility of serial BSI determinations in monitoring treatment effects. The BSI maybe particularly useful in the evaluation of agents for which prostate-specific antigen changes do not reflect clinical outcomes accurately (C) 1999 by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 00:22:52